EP2490673A2 - Amorphe rotigotin-copräzipitate - Google Patents

Amorphe rotigotin-copräzipitate

Info

Publication number
EP2490673A2
EP2490673A2 EP10784574.5A EP10784574A EP2490673A2 EP 2490673 A2 EP2490673 A2 EP 2490673A2 EP 10784574 A EP10784574 A EP 10784574A EP 2490673 A2 EP2490673 A2 EP 2490673A2
Authority
EP
European Patent Office
Prior art keywords
solvent
rotigotine
pharmaceutically acceptable
amorphous
acceptable excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10784574.5A
Other languages
English (en)
French (fr)
Inventor
Mayur Devjibhai Khunt
Udhaya Kumar
Nitin Sharadchandra Pradhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Group PTC ehf
Original Assignee
Actavis Group PTC ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group PTC ehf filed Critical Actavis Group PTC ehf
Publication of EP2490673A2 publication Critical patent/EP2490673A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

Definitions

  • the present invention relates to process for the preparation of stable amorphous co-precipitates of (-)-(S)-5-hydroxy-2-[N-n-propyl-N-2-(2- thienyl)ethylamino]tetralin (Rotigotine) with pharmaceutically acceptable excipients.
  • Rotigotine also known as (S)-rotigotine, chemically named (-)-(S)-5 -3 agonist and useful in the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease.
  • Rotigotine is represented by the following structural formula I:
  • U.S. Patent No. 4,564,628 discloses a variety of substituted 2-aminotetralin derivatives, processes for their preparation, pharmaceutical compositions and method of use thereof. These compounds are useful as dopamine agonists and, in particular, dopamine D-2 receptor agonists for the treatment of disorders of the central nervous, cardiovascular and endocrine systems such as Parkinson's disease and related disorders, hypertension and hyper- pro lactinemia. In particular, the compounds are useful in the treatment of glaucoma in mammals.
  • racemic rotigotine 5-Hydroxy-2-[N-n-propyl-N-2-(2- thienyl)ethylamino]tetralin
  • Racemic rotigotine is represented by the following structural formula:
  • racemic rotigotine contains one chiral centre (the asterisk designates the chiral centre) and therefore can be resolved into its (-) and (+) isomers (enantiomers).
  • asterisk designates the chiral centre
  • enantiomers enantiomers.
  • Various processes for the preparation of 5-hydroxy-2-[N-n-propyl-N-2-(2- thienyl)ethylamino]tetralin (racemic rotigotine) and related compounds are disclosed in U.S. Patent Nos. 4,564,628; 4,657,925; 4,885,308; 4,968,837; and 6,372,920; and European Patent No. 168505.
  • racemic rotigotine is prepared by the reaction of 5-methoxy-2- tetralon with P-(2-thienyl)ethylamine in the presence of p-toluenesulfonic acid, followed by reduction of the resulting intermediate with sodium cyanoborohydride to produce 5-methoxy- 2-[N-2-(2-thienyl)ethylamino] tetralin, which is then acylated with propionyl chloride in the presence of triethylamine in a suitable solvent to produce N-(5-methoxy-2-tetralenyl)-N-[2- (2-thienyl)ethyl)] propanamide, which is then reduced with lithium aluminum hydride to produce 5-methoxy-2-[N
  • racemic rotigotine is prepared by the reaction of 5-methoxy-2-(N-propylamino)tetralin with 2- thiophene acetic acid in the presence of borane trimethylamine complex in xylene, or with 2- thienylacetyl chloride and lithium aluminum hydride, to produce 5-methoxy-2-[N-n-propyl- N-2-(2-thienyl)ethylamino] tetralin, which is then demethylated with boron tribromide, followed by treatment with hydrochloric acid, to produce racemic rotigotine hydrochloride.
  • U.S. Patent No. 4,657,925 describes both the (-)-enantiomer and (+)- enantiomer of rotigotine, of which the levo (-) isomer is reported to be 140 times more potent than the (+)-isomer when used in therapy treatment.
  • U.S. Patent No. 4,885,308 discloses a process for preparing the two optical isomers of rotigotine by resolving racemic 2-(N-n-propylamino)-5-methoxytetralin to its two enantiomers using an appropriate optical isomer of 4-(2-chlorophenyl)-5,5-dimethyl-2- hydroxy-l,3,2-dioxaphosphorinane-2-oxide, and then converting each enantiomer to (-) and (+)- enantiomers of rotigotine, using the processes disclosed in the '628 patent.
  • U.S. Patent No. 6,372,920 (hereinafter referred to as the '920 patent) describes a process for preparing optically active and racemic nitrogen-substituted 2-aminotetralins including rotigotine.
  • (-)-(S)-5 -hydro xy-2- [N-n-propyl-N-2-(2-thienyl)ethylamino]tetralin (rotigotine) is prepared by the reaction of (-)- 5-hydroxy-N-n-propyl-2-aminotetralin with 2-(2-thienyl)ethanol toluenesulfonate in the presence of less than about 1.9-fold molar excess of an alkali metal carbonate or an alkali metal bicarbonate with respect to the amine starting material.
  • Drugs of the Future 1993, 18(11), 1005-1008 discloses a process for preparing rotigotine comprising methylation of 1,6-dihydroxynaphthalene with dimethyl sulfate to give 1,6-dimethoxynaphthalene, which is converted to 5-methoxy-2-tetralone by reduction with sodium in ethanol, which is then reductive ly aminated with propylamine to produce racemic 5-methoxy-2-N-propyl-aminotetralin, from which the (-)-enantiomer is obtained by fractional crystallization of the dibenzoyl-L-tartaric acid salt followed by demethylation with aqueous hydrobromic acid to afford (-)-(S)-5-hydroxy-2-N-propyl-aminotetralin, which is reductively alkylated with thienylacetic acid in the presence of trimethylaminoborane to produce (-)-(S)-5-hydroxy-2-[N-n-propy
  • U.S. Patent Application No. 2005/0175678 Al describes a matrix suitable for transdermal administration of levo (-) isomer of rotigotine [(-)-5,6,7,8-tetrahydro-6- [propyl[2-(2-thienyl)ethyl]amino]-l-naphthol] that is free of solvents and that comprises at least one matrix polymer and rotigotine base in a concentration above the solubility limit of the matrix polymer for rotigotine, wherein the portion of the rotigotine not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles with a maximum mean diameter of 30 ⁇ .
  • U.S. Patent Application No. 2009/0202647 Al discloses solid state forms of racemic rotigotine, process for the preparation, pharmaceutical compositions, and methods of treating thereof.
  • European Patent Application No. 2177217 Al discloses a composition containing rotigotine and the use thereof in the manufacture of a rotigotine-containing transdermal patch, wherein the composition is based on a matrix mixture system formed from a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive, and polyvinylpyrrolidone, which are present in a particular weight ratio.
  • U.S. patent No. 6,884,434 discloses a transdermal therapeutic system, comprising a backing layer inert to the components of the matrix, a self-adhesive matrix layer containing rotigotine in an effective amount, and a protective foil or sheet to be removed prior to use.
  • the transdermal therapeutic system is characterized by a matrix that is based on a non-aqueous, acrylate-based or silicone-based polymer adhesive system, and said matrix is substantially free of inorganic silicate particulates.
  • PCT Publication No. WO 2010/042152 A2 discloses a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of rotigotine substantially in amorphous form within the adhesive matrix, and a release liner.
  • Rotigotine when formulated in the form of transdermal patch, is known to undergo crystal formation which causes unreliable drug delivery.
  • amorphous co-precipitates of rotigotine with pharmaceutically acceptable excipients More particularly, disclosed herein are amorphous co-precipitates of rotigotine with improved physiochemical characteristics which help in the effective bioavailability of rotigotine.
  • compositions comprising the amorphous co-precipitates of rotigotine and one or more pharmaceutically acceptable excipients.
  • the amorphous co-precipitates of rotigotine disclosed herein for use in the pharmaceutical compositions has a D90 particle size of less than or equal to about 500 microns, specifically about 1 micron to about 300 microns, and most specifically about 5 microns to about 20 microns.
  • Figure 1 is a characteristic powder X-ray diffraction (XRD) pattern of an amorphous co-precipitate of Rotigotine with povidone (1 :2) prepared according to Example 1.
  • XRD X-ray diffraction
  • Figure 2 is a characteristic powder X-ray diffraction (XRD) pattern of an amorphous co-precipitate of Rotigotine with povidone (1 :2) prepared according to Example 2.
  • XRD X-ray diffraction
  • stable amorphous co-precipitates comprising rotigotine and a pharmaceutically acceptable excipient, having improved physio chemical characteristics that assist in the effective bioavailability of rotigotine, wherein the pharmaceutically acceptable excipient is selected from the group consisting of povidone (also known as polyvinylpyrrolidone), polyvinyl alcohol, hydroxypropyl methylcellulose, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydro xyethylcellulose, polyvinyl acetate, maltodextrins, cyclodextrins, gelatins,
  • povidone also known as polyvinylpyrrolidone
  • polyvinyl alcohol also known as polyvinylpyrrolidone
  • hydroxypropyl methylcellulose methyl cellulose
  • carboxymethyl cellulose carboxymethyl cellulose
  • sodium carboxymethyl cellulose sodium carboxymethyl cellulose
  • hydro xyethylcellulose polyvinyl acetate
  • hypromellose phthalate hypromellose phthalate, sugars, and combinations comprising one or more of the foregoing hydrophilic carriers.
  • a specific pharmaceutically acceptable excipient is povidone.
  • the povidone may be chosen from one or more of the grades such as PVP K-15, K-25, K-30, K29/32, K-60 and K-90.
  • compositions comprising amorphous co-precipitates of rotigotine, and one or more pharmaceutically acceptable excipients.
  • amorphous co-precipitates of rotigotine with a pharmaceutically acceptable excipient obtained by the process disclosed herein are characterized by their powder X-ray diffraction (XRD) pattern.
  • an amorphous co-precipitate of rotigotine with povidone characterized by a powder X-ray diffraction pattern, showing a plain halo with no well-defined peaks, substantially in accordance with any of the figures 1 and 2.
  • a solvent medium comprising a first solvent and a second solvent
  • the pharmaceutically acceptable excipient is selected from the group consisting of polyvinylpyrrolidone (povidone), polyvinyl alcohol, hydroxypropy
  • substantially removing the solvent refers to at least 80%, specifically greater than about 85%, more specifically greater than about 90%, still more specifically greater than about 99%, and most specifically essentially complete (100%), removal of the solvent from the solvent solution.
  • the amorphous co-precipitates of rotigotine obtained by the process disclosed herein are stable, consistently reproducible and have good flow properties, and which is particularly suitable for bulk preparation and handling, and so, the novel co-precipitates obtained by the process disclosed herein are suitable for formulating rotigotine.
  • the specific pharmaceutically acceptable excipient used in step-(a) is povidone.
  • the povidone may be used in one or more of the grades such as PVP K-15, K-25, K-30, K29/32, K-60 and K-90.
  • the first solvent is selected from the group consisting of methanol, ethanol, n-propanol, isopropyl alcohol, isobutanol, n-butanol, tert-butanol, amyl alcohol, isoamyl alcohol, and mixtures thereof; and the second solvent is selected from the group consisting of methylene chloride, ethylene dichloride, chloroform, and mixtures thereof.
  • the first solvent is methanol and the second solvent is methylene chloride.
  • Step-(a) of providing a solution includes dissolving any form of rotigotine in the first solvent, or such a solution may be obtained directly from a reaction in which rotigotine is formed; and combining the solution with a pharmaceutically acceptable excipient and followed by the addition of the second solvent or the solvent medium comprising the first solvent and the second solvent.
  • the pharmaceutical excipient can be dissolved in a solution containing rotigotine and the solvent medium, or, rotigotine can be dissolved in a solution containing a pharmaceutical excipient in the solvent medium.
  • a solution of rotigotine in the first solvent can be combined with a solution of a pharmaceutically acceptable excipient in the second solvent or the solvent medium comprising the first solvent and the second solvent, and the solvents used for preparing the different solutions need not be the same as long as the solvents have mutual solubility and form a single phase.
  • rotigotine should be completely soluble in the solvents used and should provide a clear solution. The presence of undissolved crystals could lead to the formation of a material that is not completely amorphous.
  • the dissolution is carried out at a temperature of about 0°C to about 1 10°C, specifically at about 20°C to about 100°C, and more specifically at about 25°C to about 80°C.
  • the solution obtained in step-(a) is optionally subjected to carbon treatment or silica gel treatment.
  • the carbon treatment or silica gel treatment is carried out by methods known in the art, for example, by stirring the solution with finely powdered carbon or silica gel at a temperature of below about 70°C for at least 15 minutes, specifically at a temperature of about 40°C to about 70°C for at least 30 minutes; and filtering the resulting mixture through hyflo to obtain a filtrate containing rotigotine and a pharmaceutically acceptable excipient by removing charcoal or silica gel.
  • finely powdered carbon is an active carbon.
  • a specific mesh size of silica gel is 40-500 mesh, and more specifically 60-120 mesh.
  • step-(a) The solution obtained in step-(a) is optionally stirred at a temperature of about 20°C to the reflux temperature of the solvent medium used for at least 20 minutes, and specifically at a temperature of about 40°C to the reflux temperature of the solvent used for about 30 minutes to about 4 hours.
  • reaction temperature means the temperature at which the solvent or solvent system refluxes or boils at atmospheric pressure.
  • Step-(c) Removal of solvent in step-(c) is accomplished, for example, by substantially complete evaporation of the solvent, concentrating the solution or distillation of solvent, under inert atmosphere to obtain the amorphous co-precipitate comprising rotigotine and a pharmaceutically acceptable excipient.
  • the solvent is removed by evaporation. Evaporation can be achieved at sub-zero temperatures by lyophilisation or freeze-drying techniques.
  • the solution may also be completely evaporated in, for example, a pilot plant Rota vapor, a Vacuum Paddle Dryer or in a conventional reactor under vacuum above about 720 mm Hg by flash evaporation techniques by using an agitated thin film dryer ("ATFD”), or evaporated by spray drying to obtain a dry amorphous powder.
  • ATFD agitated thin film dryer
  • the distillation process can be performed at atmospheric pressure or reduced pressure. Specifically, the solvent is removed at a pressure of about 760 mm Hg or less, more specifically at about 400 mm Hg or less, still more specifically at about 80 mm Hg or less, and most specifically from about 30 to about 80 mm Hg.
  • Solvents can also be removed by spray-drying, in which a solution comprising rotigotine and a pharmaceutically acceptable excipient is sprayed into the spray drier at the flow rate ranging from 10 to 300 ml/hr, specifically 40 to 200ml/hr.
  • the air inlet temperature to the spray drier used may range from about 30°C to about 150°C, specifically from about 65°C to about 110°C and the outlet air temperature used may range from about 30°C to about 90°C.
  • Another suitable method is vertical agitated thin-film drying (or evaporation).
  • Agitated thin film evaporation technology involves separating the volatile component using indirect heat transfer coupled with mechanical agitation of the flowing film under controlled conditions.
  • vertical agitated thin-film drying (or evaporation) ATFD-V
  • the starting solution is fed from the top into a cylindrical space between a centered rotary agitator and an outside heating jacket.
  • the rotor rotation agitates the downside-flowing solution while the heating jacket heats it.
  • the pure amorphous co-precipitate of rotigotine with the pharmaceutically acceptable excipient obtained by process disclosed herein may be further dried, preferably spin dried, in, for example, a Vacuum Tray Dryer, a Rotocon Vacuum Dryer, a Vacuum Paddle Dryer or a pilot plant Rota vapor, to further lower residual solvents. Drying can be carried out under reduced pressure until the residual solvent content reduces to the desired amount such as an amount that is within the limits given by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (“ICH”) guidelines.
  • ICH International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use
  • the drying is carried out at atmospheric pressure or reduced pressures, such as below about 200 mm Hg, or below about 50 mm Hg, at temperatures such as about 20°C to about 60°C.
  • the drying can be carried out for any desired time period that achieves the desired result, such as times about 1 to 20 hours, preferably 2 to 4 hours. Drying may also be carried out for shorter or longer periods of time depending on the product specifications. Temperatures and pressures will be chosen based on the volatility of the solvent being used and the foregoing should be considered as only a general guidance. Drying can be suitably carried out in a tray dryer, vacuum oven, air oven, or using a fluidized bed drier, spin flash dryer, flash dryer and the like. Drying equipment selection is well within the ordinary skill in the art.
  • the dried product obtained by the process disclosed herein above can optionally be milled to provide the desired particle sizes. Milling or micronization can be performed prior to drying, or after the completion of drying of the product. The milling operation reduces the size of the particles and increases surface area of the particles. Drying is more efficient when the particle size of the material is smaller and the surface area is higher, hence milling will frequently be performed prior to the drying operation.
  • Milling can be done suitably using jet milling equipment like an air jet mill, or using other conventional milling equipment.
  • the resulting amorphous powder compositions have improved solubility properties and hence also have improved bioavailability.
  • the amorphous co-precipitates of rotigotine with the pharmaceutically acceptable excipients obtained by the process disclosed herein are a random distribution of the rotigotine and the pharmaceutically acceptable excipient in a particle matrix. While the invention should not be constrained by any particular theory, the co-precipitates have the characteristics of solid dispersions at a molecular level, being in the nature of solid solutions. The solid solutions, or molecular dispersions, provide homogeneous particles in which no discrete areas of only amorphous rotigotine and only pharmaceutically acceptable excipient can be observed.
  • composition together with a pharmaceutically acceptable carrier.
  • the amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient disclosed herein for use in the pharmaceutical compositions has a D 90 particle size of less than or equal to about 500 microns, specifically about 1 micron to about 300 microns, and most specifically about 5 microns to about 20 microns.
  • the particle sizes of amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient can be achieved by a mechanical process of reducing the size of particles which includes any one or more of cutting, chipping, crushing, milling, grinding, micronizing, trituration or other particle size reduction methods known in the art, to bring the solid state forms the desired particle size range.
  • a method for treating a patient suffering from disorders of the central nervous, cardiovascular and endocrine systems such as Parkinson's disease and related disorders, hypertension and hyperprolactinemia; comprising administering a therapeutically effective amount of the amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient, or a pharmaceutical composition that comprises a therapeutically effective amount of amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient, along with other pharmaceutically acceptable excipients.
  • compositions comprising amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient prepared according to processes disclosed herein and one or more pharmaceutically acceptable excipients.
  • a process for preparing a pharmaceutical formulation comprising combining an amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient prepared according to processes disclosed herein, with one or more pharmaceutically acceptable excipients.
  • compositions comprise at least a therapeutically effective amount of the amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient adapted for administration to the patient by
  • compositions further contain one or more
  • Suitable excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
  • the route of administration can be parenteral, transdermal or transmucosal.
  • the route of administering the amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient is transdermal administration.
  • the form and pharmaceutical composition in which the compound is administered is adapted for the route of administration and, in the case of transdermal administration, a suitable composition can be, for example, an ointment, a gel, a cream, a paste, a spray, a film, a plaster, a patch, a poultice, a cataplasm or an iontophoretic device.
  • amorphous co-precipitate of rotigotine with a pharmaceutically acceptable excipient may be administered by application to a patient's skin of a patch or plaster having the active substance present in an adhesive polymer matrix, for instance a self-adhesive polysiloxane matrix.
  • transdermal therapeutic system refers to a pharmaceutical composition, in a form of one to a plurality of patch or plaster formulations, that contains an active agent, for example amorphous co -precipitate of rotigotine with a pharmaceutically acceptable excipient, and that when applied to skin of a subject delivers at least a portion of the active agent into and across the skin, where the active agent accesses the circulatory system of the subject.
  • TTS transdermal therapeutic system
  • a transdermal therapeutic system useful herein can be prepared by processes known in the art.
  • Rotigotine free base 500 mg was dissolved in methanol (10 ml) at 20-25°C to form a clear solution.
  • Povidone(K-30) (1 gm) was added to the resulting solution and followed by the addition of methanol (5 ml) and dichloro methane (10 ml) to form a clear solution.
  • the resulting solution was distilled up to 90-95% in a rotavapour under vacuum at 30-35°C bath temperature until the indication of isolation of an oily material.
  • the remaining solution was distilled at 20-25 °C in rotavapour under vacuum and the distillation was continued at 20-25°C for 30 minutes to produce a foamy white solid.
  • the foamy white solid was further spin dried in rotavapour at 20-25°C for another 2 hours to give an amorphous coprecipitate of rotigotine with povidone.
  • Rotigotine free base 500 mg was dissolved in methanol (15 ml) at 20-25°C to form a clear solution.
  • Povidone-(K-30) (1 gm) was added to the resulting solution and followed by the addition of dichloromethane (10 ml) to form clear solution.
  • the clear solution was distilled completely in rotavapour under vacuum at 0-5°C bath temperature until the indication of isolation of oily material. The distillation was continued at 20-25°C for 30 minutes to produce a foamy white solid.
  • the foamy white solid was further spin dried in rotavapour at 20-25°C for another 2 hours to give amorphous coprecipitate of rotigotine with povidone.
  • pharmaceutically acceptable means that which is useful in preparing a pharmaceutical composition that is generally non-toxic and is not biologically undesirable and includes that which is acceptable for veterinary use and/or human pharmaceutical use.
  • composition is intended to encompass a drug product including the active ingredient(s), pharmaceutically acceptable excipients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients. Accordingly, the pharmaceutical compositions encompass any composition made by admixing the active ingredient, active ingredient dispersion or composite, additional active ingredient(s), and pharmaceutically acceptable excipients.
  • terapéuticaally effective amount means the amount of a compound that, when administered to a mammal for treating a state, disorder or condition, is sufficient to effect such treatment.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the mammal to be treated.
  • micronization means a process or method by which the size of a population of particles is reduced.
  • micron As used herein, the term “micron” or “ ⁇ ” both are same refers to
  • micrometer which is lxlO "6 meter.
  • P.S.D particle Size Distribution
  • the important characteristics of the PSD are the (D90), which is the size, in microns, below which 90% of the particles by volume are found, and the (D 50 ), which is the size, in microns, below which 50%> of the particles by volume are found.
  • a D 90 or d(0.9) of less than 300 microns means that 90 volume -percent of the particles in a composition have a diameter less than 300 microns.
  • co-precipitate or co -precipitate refers to
  • compositions comprising amorphous rotigotine together with at least one pharmaceutically acceptable excipient, being prepared by removing solvent from a solution containing both of them.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP10784574.5A 2009-10-19 2010-10-18 Amorphe rotigotin-copräzipitate Withdrawn EP2490673A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2527CH2009 2009-10-19
PCT/IB2010/002844 WO2011048491A2 (en) 2009-10-19 2010-10-18 Amorphous rotigotine co-precipitates

Publications (1)

Publication Number Publication Date
EP2490673A2 true EP2490673A2 (de) 2012-08-29

Family

ID=43402066

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10784574.5A Withdrawn EP2490673A2 (de) 2009-10-19 2010-10-18 Amorphe rotigotin-copräzipitate

Country Status (2)

Country Link
EP (1) EP2490673A2 (de)
WO (1) WO2011048491A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016842A1 (en) * 2012-07-23 2014-01-30 Symed Labs Limited Amorphous coprecipitates of rivaroxaban
WO2017106130A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564628A (en) 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US4657925A (en) 1984-08-13 1987-04-14 Nelson Research & Development Co. Method and compositions for reducing the intraocular pressure of mammals
DE3479314D1 (en) 1984-05-22 1989-09-14 Nelson Res & Dev Substituted 2-aminotetralins and processes for synthesis
US4885308A (en) 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
US4968837A (en) 1989-07-28 1990-11-06 Ethyl Corporation Resolution of racemic mixtures
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
HK1052514A1 (zh) 1999-11-23 2003-09-19 阿德里斯制药公司 制备氮取代的氨基1，2，3，4-四氢化萘的改进方法
EP1256339B1 (de) * 2001-05-08 2003-10-15 Schwarz Pharma Ag Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
US20090202647A1 (en) 2008-02-11 2009-08-13 Mayur Devjibhai Khunt Solid form of racemic rotigotine
EP2133068A1 (de) * 2008-06-13 2009-12-16 Ratiopharm GmbH Verfahren zur Auswahl eines geeigneten Hilfsstoffs für die Herstellung von festen Dispersionen für pharmazeutische Formulierungen
JP2012504609A (ja) 2008-10-06 2012-02-23 マイラン・テクノロジーズ，インコーポレイテッド アモルファスロチゴチン経皮システム

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011048491A2 *

Also Published As

Publication number Publication date
WO2011048491A3 (en) 2011-12-29
WO2011048491A2 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
JP5391204B2 (ja) ロチゴチンの多形体
CN102716493B (zh) 含无定型态阿戈美拉汀的共聚物、其制备方法、其药物组合物及用途
EP2271612B1 (de) Rasagilinmesylatpartikel und verfahren zu deren herstellung
US20100272815A1 (en) Amorphous form of tapentadol hydrochloride
US20160194301A1 (en) Preparation of lenalidomide
CN102958911B (zh) 阿戈美拉汀氯化氢水合物及其制备方法
US9249134B2 (en) Process for preparation of amorphous form of dasatinib
BRPI0713053A2 (pt) métodos para a preparação de compostos biologicamente ativos na forma nanoparticulada
WO2010073124A2 (en) Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
JP2009541362A (ja) ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
CN110621662A (zh) 一种盐的结晶性固体形式、制备工艺和使用方法
WO2012013088A1 (zh) 决奈达隆固体分散体及其制备方法
US20120053246A1 (en) Purification process for preparing highly pure arformoterol tartrate substantially free of desformyl impurity
CN103476742A (zh) 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
WO2011048491A2 (en) Amorphous rotigotine co-precipitates
US8835635B2 (en) Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
US20090202647A1 (en) Solid form of racemic rotigotine
US20110014246A1 (en) Amorphous arformoterol l-(+)-tartrate
WO2012126386A1 (zh) 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
CN104379557B (zh) 阿戈美拉汀晶型i的制备方法
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
TW202342434A (zh) 卡利拉嗪藥用鹽及其晶型、藥物組合物、製備方法和用途
CN105315230B (zh) 无定型形态的匹维溴铵
CN115322150A (zh) 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
CN102030743A (zh) 伊潘立酮晶体、其制备方法及药物组合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120413

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121205